Loading clinical trials...

AG & IM in CA Stomach Protocol | Clinical Trials | Clareo Health

UNKNOWN

AG & IM in CA Stomach Protocol

Performance of Endoscopic and Histological Criteria of Atrophic Gastritis and Intestinal Metaplasia in Predicting Risk of Gastric Cancer - a Multicenter Case Control Study

NCT04184960•Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

This is a multi-center prospective case control study aiming to compare different methods of risk stratification models in predicting the risk of gastric cancer development.

Detailed Description

The case control study would compare which type of assessment (Endoscopic / histological) is more accurate in predicting the risk of gastric cancer development. The risk factor assessment would be based on the following criteria. Endoscopic assessment: 1. Atrophic gastritis, based on Kimura Takemoto Classification 2. Kyoto classification of gastritis 3. Intestinal metaplasia, based on Endoscopic Mapping and Grading of Intestinal Metaplasia (EGGIM) Histological assessment (Based on random biopsies) 1\. Operative Links on Gastritis Assessment 2. Operative Links on Gastric Intestinal Metaplasia

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Two groups of patients would be recruited in this case control study.
•1. Gastric neoplasia group Patients with newly diagnosed or history of cancer of stomach or gastric high grade dysplasia.
•2. Control group Patients with no prior history of gastric dysplasia or cancer
•1. Age 40 or above
•2. Undergo elective upper gastrointestinal endoscopy

Exclusion Criteria

•1. Patients with history of gastrectomy
•2. Patients with severe thrombocytopenia (Platelet count \<50) or coagulopathy (INR \> 1.5 or on anticoagulation)
•3. Contraindication to upper gastrointestinal endoscopy
•4. Allergy towards sedative agents (Midazolam / Diazepam) or local anaesthetic spray (Lignocaine)
•5. Patients who cannot give informed consent

Locations (4)

Prince of Wales Hospital

Hong Kong, Hong Kong

Osaka International Cancer Institute

Osaka, Japan

Changi General Hospital

Singapore, Singapore

King Chulalongkorn Memorial Hospital and Chulalongkorn University

Bangkok, Thailand

Key Dates

Start Date

December 5, 2019

Primary Completion Date

January 31, 2024

Completion Date

March 31, 2024

Last Updated

September 7, 2023

Enrollment

400

ESTIMATED participants

Conditions

Gastric CancerAtrophic GastritisIntestinal Metaplasia

Interventions

Gastroscopy and gastric biopsies

DIAGNOSTIC_TEST

Contacts

Hon Chi Yip, FRCSEd(Gen)

CONTACT

+852 35052627 hcyip@surgery.cuhk.edu.hk

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AG & IM in CA Stomach Protocol

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Resilience and Equity in Aging, Cancer, and Health (REACH)

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.